Cleared Traditional

K821411 - HISTOSET IMMUNOPEROFIDASE TISSUE

K821411 is the FDA 510(k) clearance for HISTOSET IMMUNOPEROFIDASE TISSUE by Immulok, Inc.. It is a Class 2 Pathology device (product code GQL) cleared through the Traditional 510(k) pathway after a 44-day FDA review.

K821411 · Immulok, Inc. · Pathology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1982
Decision
44d
Days
Class 2
Risk

K821411 is an FDA 510(k) clearance for the HISTOSET IMMUNOPEROFIDASE TISSUE. Classified as Antisera, Fluorescent, Herpesvirus Hominis 1,2 (product code GQL), Class II - Special Controls.

Submitted by Immulok, Inc. (Mchenry, US). The FDA issued a Cleared decision on June 25, 1982 after a review of 44 days - a notably fast clearance cycle.

This device falls under the Pathology FDA review panel, regulated under 21 CFR 866.3305 - the FDA pathology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Immulok, Inc. devices

Submission Details

510(k) Number K821411 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 12, 1982
Decision Date June 25, 1982
Days to Decision 44 days
Submission Type Traditional
Review Panel Pathology (PA)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
33d faster than avg
Panel avg: 77d · This submission: 44d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GQL Antisera, Fluorescent, Herpesvirus Hominis 1,2
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3305
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Pathology devices follow this clearance model.

Regulatory Peers - GQL Antisera, Fluorescent, Herpesvirus Hominis 1,2

All 25
Devices cleared under the same product code (GQL) and FDA review panel - the closest regulatory comparables to K821411.
HSV IGM TEST
K830865 · Gull Laboratories, Inc. · Jul 1983
INDIRECT FLUORO-KIT HSV
K830623 · Clinical Sciences, Inc. · Jul 1983
MICRO TRAK HSV1 & 2 CULTURE CONFIRMATION
K830953 · Syva Co. · Jun 1983
HERPES VIRUS HOMINIS ANTIBODY TEST SYS.
K812085 · Zeus Scientific, Inc. · Sep 1981
FIAX TEST KIT FOR HERPES SIMPLEX VIRUS
K792559 · Intl. Diagnostic Technology · Mar 1980
HERPES I.D. TM TEST
K771445 · Hyland Therapeutic Div., Travenol Laboratories · Dec 1977